Poolbeg Pharma identifies new RSV drug candidates

Digital Asset Direct by Poolbeg Pharma PLC

London, UK | December 22, 2022 05:47 AM Eastern Standard Time

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing that Poolbeg has identified several potential candidates from its Respiratory Syncytial Virus (RSV) AI collaboration with One Three Biotech. He also looks back on what the company achieved during 2022 and looks ahead to what investors can expect from Poolbeg in 2023.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Why News Direct

For Public Relations For Investor Relations Testimonials

About us Features News Hub

Resources

Press Blog

Why News Direct For Public Relations For Investor Relations Testimonials

What We Offer Collaborative Content Studio Advanced News Release Capability Standalone Multimedia Distribution Industry-Leading Security Unsurpassed Global Reach Actionable Analytics Synergistic PR Solutions

Pricing About us News Hub

Resources Blog Press